In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi

FEMS Microbiology Letters

Volumn 307, Issue 2, 2010, Pages 175-184

  Nyilasi, Ildikó ^a,b   Kocsubé, Sándor ^a,b   Krizsán, Krisztina ^a   Galgóczy, László ^a   Pesti, Miklós ^c   Papp, Tamás ^a   Vágvölgyi, Csaba ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b PannonPharma Ltd   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antifungal effect; Azole; Drug combination; Statin; Synergism

Indexed keywords

ATORVASTATIN; ATORVOX; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MICONAZOLE; PRAVASTATIN; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VASILIP; ANTIFUNGAL AGENT; PIPERAZINE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS GROWTH; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOLOGY; NONHUMAN; PAECILOMYCES; PRIORITY JOURNAL; RHIZOPUS ORYZAE; ASPERGILLUS; CANDIDA; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; RHIZOMUCOR; SPECIES DIFFERENCE;

FUNGI;

ANTIFUNGAL AGENTS; ASPERGILLUS; AZOLES; CANDIDA; DRUG SYNERGISM; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; PIPERAZINES; RHIZOMUCOR; SPECIES SPECIFICITY;

EID: 77952633047     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/j.1574-6968.2010.01972.x     Document Type: Article

References (37)

1. Afeltra J Verweij PE (2003) Antifungal activity of nonantifungal drugs. Eur J Clin Microbiol 22: 397-407.
2. Chamilos G, Lewis RE Kontoyiannis DP (2006) Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Ch 50: 96-103.
3. Chayakulkeeree M, Ghannoum MA Perfect JR (2006) Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol 25: 215-229.
4. Chin NX, Weitzman I Della-Latta P (1997) In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Ch 41: 850-852.
5. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A Landreth G (2005) Mechanism of statin-mediated inhibition of small G-protein function. J Biol Chem 280: 34202-34209.
6. Falagas ME, Makris GC, Matthaiou DK Rafailidis PI (2008) Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemoth 61: 774-785.
7. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck J-P Robinson WT (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 27: 410-416.
8. Galgóczy L, Papp T, Lukács G, Leiter É, Pócsi I Vágvölgyi C (2007) Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett 270: 109-115.
9. Galgóczy L, Kovács L, Krizsán K, Papp T Vágvölgyi C (2009a) Inhibitory effects of cysteine and cysteine derivatives on germination of sporangiospores and hyphal growth of different Zygomycetes. Mycopathologia 168: 125-134.
10. Galgóczy L, Nyilasi I, Papp T Vágvölgyi C (2009b) Are statins applicable for prevention and treatment of zygomycosis? Clin Infect Dis 49: 483-484.
11. Gisi U (1996) Synergistic interaction of fungicides in mixtures. Phytopathology 86: 1273-1279.
12. Gyetvai Á, Emri T, Takács K, Dergez T, Fekete A, Pesti M, Pócsi I Lenkey B (2006) Lovastatin possesses a fungistatic effect against Candida albicans but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res 6: 1140-1148.
13. Herman RJ (1999) Drug interactions and the statins. Can Med Assoc J 161: 1281-1286.
14. Kauffman CA (2004) Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 39: 588-590.
15. Kivistö KT, Kantola T Neuvonen PJ (1998) Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Brit J Clin Pharmaco 46: 49-53.
16. Kontoyiannis DP (2007) Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis 44: 1089-1090.
17. Liao JK Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol 45: 89-118.
18. Lorenz RT Parks LW (1990) Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Ch 34: 1660-1665.
19. Lukács G, Papp T, Nyilasi I, Nagy E Vágvölgyi C (2004) Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 42: 5400-5402.
20. Macreadie IG, Johnson G, Schlosser T Macreadie PI (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262: 9-13.
21. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal BSV, Lettieri J Sundaresen P (2000) Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 68: 391-400.
22. Miida T, Hirayama S Nakamura Y (2004) Cholesterol-independent effects of statins and new therapeutic strategies: ischemic stroke and dementia. J Atheroscler Thromb 11: 253-264.
23. Nash JD, Burgess DS Talbert RL (2002) Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 51: 105-109.
24. Natesan SK, Chandrasekar PH, Alangaden GJ Manavathu EK (2008) Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Micr Infec Dis 60: 369-373.
25. NCCLS (1997) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, Document M27-A. National Committee for Clinical Laboratory Standards
26. NCCLS (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Approved Standard, Document M38-A. National Committee for Clinical Laboratory Standards
27. Nosanchuk JD (2006) Current status and future of antifungal therapy for systemic mycoses. Recent Patents Anti-Infect Drug Disc 1: 75-84.
28. Nyilasi I, Kocsubé S, Pesti M, Lukács G, Papp T Vágvölgyi C (2010) In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J Med Microbiol 59: 200-205.
29. Pfaller MA, Messer SA Coffmann S (1995) Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D070. J Clin Microbiol 33: 1094-1097.
30. Rex JH, Pfaller MA, Rinaldi MG, Polak A Galgiani JN (1993) Antifungal susceptibility testing. Clin Microbiol Rev 6: 367-381.
31. Ribes JA, Vanhover-Sams CL Baker DJ (2000) Zygomycetes in human disease. Clin Microbiol Rev 13: 236-301.
32. Roze LV Linz JE (1998) Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 25: 119-133.
33. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharm 19: 117-125.
34. Singh N (2001) Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33: 1692-1696.
35. Sun H-Y Singh N (2009) Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis 48: 745-755.
36. Triscari J, O'Donnell D, Zinny M Pan HY (1995) Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 35: 142-144.
37. Walsh TJ Groll AH (1999) Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1: 247 261.